Neurogene Inc. (NGNE) vs YD Bio Limited Ordinary Shares (YDES)

A side-by-side comparison of Neurogene Inc. and YD Bio Limited Ordinary Shares across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Neurogene Inc. logo
NGNE
Neurogene Inc.
$402M
$25.45HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
YD Bio Limited Ordinary Shares logo
YDES
YD Bio Limited Ordinary Shares
$436M
$6.15HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — NGNE vs YDES

growth of $100 · dividends reinvested · last 1y
NGNE +21.5% (+21.5%/yr)YDES -40.9% (-40.9%/yr)NGNE compounded faster over this window
50100150200Start $1002026$122$59
NGNE YDES

NGNE vs YDES: by the numbers

  • •YDES is the larger company ($436M vs $402M market cap).
  • •Both run net losses; NGNE's is the smaller (0.00% vs -1392.61% net margin).

Metrics side by side

Valuation

MetricNGNEYDES
P/B ratio1.85N/A

Profitability

MetricNGNEYDES
Gross margin0.00%-7.06%
Operating margin0.00%-883.31%
Net margin0.00%-1392.61%
ROE-51.17%-66.49%
ROIC-54.45%N/A

Growth (annualized)

MetricNGNEYDES
Total return CAGR (5Y)-27.73%N/A

Go deeper

Full NGNE analysisFull YDES analysisInteractive comparison tool

Dig into the metrics

Neurogene ROEYD Bio Limited Ordinary Shares ROENeurogene operating marginYD Bio Limited Ordinary Shares operating marginNeurogene revenue growthYD Bio Limited Ordinary Shares revenue growthNeurogene free cash flowYD Bio Limited Ordinary Shares free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.